Finance David Craik · 8 March 2018
Life sciences entrepreneurs targeted with new 50m venture capital fund
Britain’s life sciences entrepreneurs are the target of a new 50m venture capital fund aimed at boosting the nation’s health. Launched today NCL Technology Ventures? fund, which is backed by Kent County Council, will invest in high-growth small and medium-sized firms with a focus on game-changing medical technologies and advanced therapeutics. The Kent Life Science Fund is NCL’s second investment scheme. It said it is aiming to attract companies looking to establish a UK operating base as part of global expansion plans. britain is an innovation nation; supporting and growing the UK life sciences sector is vital if we want to thrive after Brexit. This will give a shot in the arm to the sector, saidjonathan Synett, investment director. we are at the forefront of a radical change in new medical technologies and therapeutics, from robotics to revolutionary cancer treatments. these advances will benefit millions of people and were looking to invest in start-ups and SMEs, so they can scale up and reach the NHS and other markets with their cutting-edge innovations.. The group’s first Discovery Park Fund invested 5m into eight small UK-based firms which now have operations at NCL’s pharmaceutical facility at Discovery Park, Kent, a 1.4m square foot complex. New firms brought in by the fund will be given space to work at the complex.